quinta-feira, 1 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 26, 2026

Eos Energy Enterprises Reports Fourth Quarter and Full Year 2025 Financial Results; Delivers More than 7x Year-Over-Year Revenue Growth and Initiates 2026 Revenue Guidance

View original at globenewswire.com
Eos Energy Enterprises Reports Fourth Quarter and Full Year 2025 Financial Results; Delivers More than 7x Year-Over-Year Revenue Growth and Initiates 2026 Revenue Guidance $58.0 million in record quarterly revenue with Q4 exceeding the first three 2025 quarters combined Secured over $240 million with nearly 1.1 GWh of…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In 2026, focus is on disciplined scale and margin improvement — driving manufacturing efficiency, improving unit economics quarter-over-quarter, and converting backlog into high-quality revenue

    80% confidence
  • 2025 was a structural turning point for Eos with accelerated production, expanded annual capacity to 2 GWh, record quarterly revenue, strengthened cash position to over $600 million, and secured more than $240 million in fourth quarter bookings

    80% confidence
  • Indensity is designed to be cost competitive with incumbent storage technologies while delivering long-duration performance and non-flammable chemistry advantages

    80% confidence
  • With a strengthened balance sheet and improving cost profile, the company is positioned to transition from accelerated growth to sustainable value creation

    80% confidence
  • While disappointed in not meeting revenue expectations, execution improved significantly as 2025 progressed, and the company exited the year with clear operational momentum

    80% confidence
  • Eos expects to achieve revenue between $300 million and $400 million for full year 2026

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,317 documentos-fonte arquivados
Consulte estes dados → isubstrate.com